Roger Zheng
Senior Analyst at CD Capital- Claim this Profile
Click to upgrade to our gold package
for the full feature experience.
Topline Score
Bio
Experience
-
CD Capital
-
China
-
Venture Capital and Private Equity Principals
-
1 - 100 Employee
-
Senior Analyst
-
Aug 2021 - Present
-
-
-
IQVIA
-
United States
-
Hospitals and Health Care
-
700 & Above Employee
-
Associate Consultant
-
May 2018 - Feb 2021
2018 - Now Associate Consultant, IQVIA, Shanghai Job description: Proposal writing, desk research, project management, physician interview, data analysis, report delivery Core member for 9 projects including cancer, neuro disorder and supplies areas, besides involved in more than 10+ projects; total volume is more than 6m RMB. Market Understanding Endo-surgery stapler line buttress market opportunity • Estimated the clinical evaluation and current market coverage and usage of existing buttress products to help decide the value of acquiring potential target • Explored the unmet needs for surgeons using stapler line and tested the acceptance of new product • Suggested GI surgery as the most potential department and designed messages for new product Launch Strategy Development Product positioning, physician segmentation and messaging of PD-1 product • Understood the competitive landscape, physician’s mindset and perception of current IO products • Built physician segmentation and defined the profiles which have been recognised by global team • Designed and tested the message bundles of PD-1 product and set the KPI baseline for this product Formulation Update Anti-HER2 portfolio launch planning strategy • Explored the market potential of trastuzumab SC and anti-HER2 FDC SC to defend biosimilars • Tested the pricing sensitivity of SC and acceptance of improving turn-over rate by using SC • Found the main stakeholders in the hospital listing and the challenges for SC products market entry Pipeline Expansion AED family pre-launch KPI setting and performance management • Assessed the total AED IV market and the opportunities of LEV IV in neuro surgery • Understood the gap between lacosamide strategy and physician’s usage and attitudes • Provided deep epilepsy market insights that AEDs with better safety were using in the first line Show less
-
-
Education
-
Imperial College London
Master's degree, Molecular Medicine -
University of Liverpool
Bachelor's degree, Biochemistry